EX-99.4 3 dawn-ex99_4.htm EX-99.4 EX-99.4

 

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

On January 6, 2026, or the Closing Date, Day One Biopharmaceuticals, Inc., or the Company or Day One, completed the acquisition, or Acquisition, of Mersana Therapeutics, Inc., or Mersana. The following unaudited pro forma condensed combined statements of operations (pro forma statements of operations) and condensed combined balance sheet (pro forma balance sheet) give effect to the Acquisition, described in Note 1, and were prepared in accordance with the requirements of Article 11 of Regulation S-X.

 

The unaudited pro forma condensed combined financial information gives effect to the accounting for the Acquisition, including the pro forma adjustments intended to illustrate the estimated effects of the Acquisition, or the Transaction Accounting Adjustments or Adjustments, as defined in Article 11 of Regulation S-X and do not include any revenue and operating synergies or cost savings that may result from the Acquisition. Management is undertaking certain terminations of employees and expects to incur approximately $9.0 million in severance cost. The pro forma balance sheet as of September 30, 2025, combines the historical balance sheet for the Company and Mersana and is presented as if the Acquisition had occurred on September 30, 2025. The pro forma statements of operations for the nine months ended September 30, 2025, and for the year ended December 31, 2024, are presented as if the Acquisition took place as of January 1, 2024.

 

The following unaudited pro forma condensed combined financial information was prepared in accordance with Article 11 of Regulation S-X using accounting policies in accordance with U.S. Generally Accepted Accounting Principles, or U.S. GAAP. The unaudited pro forma condensed combined financial information (1) was prepared using the acquisition method of accounting pursuant to Accounting Standards Codification 805, Business Combinations, or ASC 805, with the Company being the accounting acquirer, and (2) is based on the Company and Mersana’s historical consolidated financial statements, as adjusted, to present the pro forma impact of the Acquisition.

 

In accordance with ASC 805, the Company used best estimates and assumptions to accurately assign fair value to the tangible assets acquired and liabilities assumed, identifiable intangible assets, consideration associated with the contingent value right, or CVR, and the related income tax impacts as of the Acquisition date. The estimate of the excess purchase price over the fair value of net tangible assets acquired was allocated to identifiable intangible assets and goodwill. The fair values assigned to Mersana's tangible and identifiable intangible assets acquired and liabilities assumed are based on the Company’s estimates and assumptions. The estimated fair values of these assets acquired and liabilities assumed are considered preliminary and are based on the information that was available as of the date of the Acquisition. In the opinion of the Company’s management, the unaudited pro forma condensed combined financial information includes all material adjustments necessary to be in accordance with Article 11 of Regulation S-X. The Company intends to finalize the acquisition accounting as soon as practicable within the required measurement period, but in no event later than one year following the Closing Date. The Company is not required to, and currently does not intend to, update these pro forma results as presented herein for any of these changes.

 

The unaudited pro forma condensed combined financial information is presented for informational purposes only. Such information is not necessarily indicative of the operating results or financial position that would have been achieved if the Acquisition had been consummated on the dates indicated, or that the combined company may achieve in future periods.

 

The following unaudited pro forma condensed combined financial information as of and for the nine months ended September 30, 2025, and for the year ended December 31, 2024, is derived from:

 

the historical unaudited Condensed Financial Statements and accompanying notes of Day One as of and for the nine months ended September 30, 2025, included in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, as filed with the SEC on November 4, 2025;
the historical audited Financial Statements and accompanying notes of Day One as of and for the year ended December 31, 2024, included in its Annual Report on Form 10-K/A for the year ended December 31, 2024, as filed with the SEC on March 6, 2025;
the historical unaudited Condensed Consolidated Financial Statements and accompanying notes of Mersana as of and for the nine months ended September 30, 2025, included in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, as filed with the SEC on November 14, 2025; and
the historical audited Consolidated Financial Statements and accompanying notes of Mersana as of and for the year ended December 31, 2024, included in its Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 3, 2025.

 


The Company has performed a preliminary review of the accounting policies of Mersana to assess alignment with the Company’s accounting policies and U.S. GAAP. Based on this preliminary review, no material differences in accounting policies were identified that would require adjustment to conform to the Company’s accounting policies for purposes of the accompanying unaudited pro forma condensed combined financial information. The Company will continue to evaluate the accounting policies as additional information becomes available, and adjustments may be identified in future periods.

 

All terms defined in this section of the report are used solely for the purposes of this section and do not apply to any other section of this Current Report on Form 8-K/A.


UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

As of September 30, 2025

(in thousands)

 

 

 

Day One

 

 

Mersana

 

 

Transaction Accounting Adjustments

 

 

Note 4

 

Pro Forma
Combined

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

43,277

 

 

$

56,391

 

 

$

81,750

 

 

(a)

 

$

56,391

 

 

 

 

 

 

 

 

 

 

(125,027

)

 

(b)

 

 

 

Short-term investments

 

 

408,303

 

 

 

 

 

 

(81,750

)

 

(a)

 

 

326,553

 

Accounts receivable, net

 

 

16,697

 

 

 

168

 

 

 

 

 

 

 

 

16,865

 

Inventory

 

 

7,061

 

 

 

 

 

 

 

 

 

 

 

7,061

 

Prepaid expenses and other current assets

 

 

14,633

 

 

 

3,429

 

 

 

(1,289

)

 

(c)

 

 

16,773

 

Total current assets

 

 

489,971

 

 

 

59,988

 

 

 

(126,316

)

 

 

 

 

423,643

 

Property and equipment, net

 

 

2,227

 

 

 

163

 

 

 

 

 

 

 

 

2,390

 

Operating lease right-of-use asset

 

 

2,450

 

 

 

2,035

 

 

 

(2,035

)

 

(d)

 

 

2,450

 

Intangible assets, net

 

 

18,815

 

 

 

 

 

 

196,850

 

 

(e)

 

 

215,665

 

Goodwill

 

 

 

 

 

 

 

 

36,745

 

 

(f)

 

 

36,745

 

Deposits and other long-term assets

 

 

317

 

 

 

500

 

 

 

 

 

 

 

 

817

 

Total assets

 

$

513,780

 

 

$

62,686

 

 

$

105,244

 

 

 

 

$

681,710

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

5,778

 

 

$

2,393

 

 

$

 

 

 

 

$

8,171

 

Accrued expenses and other current liabilities

 

 

48,210

 

 

 

14,813

 

 

 

8,531

 

 

(g)

 

 

71,554

 

Current portion of deferred revenue

 

 

2,317

 

 

 

23,770

 

 

 

 

 

 

 

 

26,087

 

Current portion of contingent consideration

 

 

 

 

 

 

 

 

8,300

 

 

(b)

 

 

8,300

 

Current portion of operating lease liabilities

 

 

161

 

 

 

2,293

 

 

 

(2,293

)

 

(d)

 

 

161

 

Total current liabilities

 

 

56,466

 

 

 

43,269

 

 

 

14,538

 

 

 

 

 

114,273

 

Long-term portion of deferred revenue

 

 

2,953

 

 

 

78,954

 

 

 

 

 

 

 

 

81,907

 

Long-term portion of contingent consideration

 

 

 

 

 

 

 

 

39,700

 

 

(b)

 

 

39,700

 

Long-term portion of operating lease liabilities

 

 

2,732

 

 

 

 

 

 

 

 

 

 

 

2,732

 

Other long-term liability

 

 

761

 

 

 

 

 

 

 

 

 

 

 

761

 

Total liabilities

 

 

62,912

 

 

 

122,223

 

 

 

54,238

 

 

 

 

 

239,373

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

 

10

 

 

 

 

 

 

 

 

(h)

 

 

10

 

Additional paid-in-capital

 

 

1,090,914

 

 

 

891,980

 

 

 

(891,980

)

 

(h)

 

 

1,090,914

 

Accumulated other comprehensive income

 

 

69

 

 

 

 

 

 

 

 

 

 

 

69

 

Accumulated deficit

 

 

(640,125

)

 

 

(951,517

)

 

 

951,517

 

 

(h)

 

 

(648,656

)

 

 

 

 

 

 

 

 

 

(8,531

)

 

(g)

 

 

 

Total stockholders’ equity

 

 

450,868

 

 

 

(59,537

)

 

 

51,006

 

 

 

 

 

442,337

 

Total liabilities and stockholders' equity

 

$

513,780

 

 

$

62,686

 

 

$

105,244

 

 

 

 

$

681,710

 

 


UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

For the nine months ended September 30, 2025

(in thousands, except per share data)

 

 

 

Day One

 

 

Mersana

 

 

Transaction Accounting Adjustments

 

 

Note 4

 

Pro Forma
Combined

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue, net

 

$

102,587

 

 

$

 

 

 

 

 

 

 

$

102,587

 

License revenue

 

 

1,877

 

 

 

16,819

 

 

 

 

 

 

 

 

18,696

 

Total revenues

 

 

104,464

 

 

 

16,819

 

 

 

 

 

 

 

 

121,283

 

Cost and operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product and license revenue

 

 

11,129

 

 

 

 

 

 

 

 

 

 

 

11,129

 

Research and development

 

 

107,187

 

 

 

46,741

 

 

 

 

 

 

 

 

153,928

 

Selling, general and administrative

 

 

86,440

 

 

 

22,643

 

 

 

986

 

 

(i)

 

 

110,069

 

Restructuring expense

 

 

 

 

 

4,131

 

 

 

 

 

 

 

 

4,131

 

Total cost and operating expenses

 

 

204,756

 

 

 

73,515

 

 

 

 

 

 

 

 

279,257

 

Loss from operations

 

 

(100,292

)

 

 

(56,696

)

 

 

 

 

 

 

 

(157,974

)

Non-operating income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Investment income, net

 

 

14,324

 

 

 

2,575

 

 

 

(2,873

)

 

(j)

 

 

14,026

 

Interest expense

 

 

 

 

 

(1,843

)

 

 

 

 

 

 

 

(1,843

)

Other expense, net

 

 

(76

)

 

 

 

 

 

 

 

 

 

 

(76

)

Total non-operating income, net

 

 

14,248

 

 

 

732

 

 

 

 

 

 

 

 

12,107

 

Loss before income taxes

 

 

(86,044

)

 

 

(55,964

)

 

 

 

 

 

 

 

(145,867

)

Income tax expense

 

 

 

 

 

 

 

 

 

 

(k)

 

 

 

Net loss

 

 

(86,044

)

 

 

(55,964

)

 

 

 

 

 

 

 

(145,867

)

Net loss per share - basic

 

$

(0.83

)

 

 

 

 

 

 

 

 

 

$

(1.42

)

Net loss per share - diluted

 

$

(0.83

)

 

 

 

 

 

 

 

 

 

$

(1.42

)

Weighted-average number of common shares used in net loss per share - basic

 

 

103,056,046

 

 

 

 

 

 

 

 

 

 

 

103,056,046

 

Weighted-average number of common shares used in net loss per share - diluted

 

 

103,056,046

 

 

 

 

 

 

 

 

 

 

 

103,056,046

 

 


UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

For the year ended December 31, 2024

(in thousands, except per share data)

 

 

 

Day One

 

 

Mersana

 

 

Transaction Accounting Adjustments

 

 

Note 4

 

Pro Forma
Combined

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue, net

 

$

57,217

 

 

$

 

 

 

 

 

 

 

$

57,217

 

License revenue

 

 

73,944

 

 

 

40,497

 

 

 

 

 

 

 

 

114,441

 

Total revenues

 

 

131,161

 

 

 

40,497

 

 

 

 

 

 

 

 

171,658

 

Cost and operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product and license revenue

 

 

5,279

 

 

 

 

 

 

 

 

 

 

 

5,279

 

Research and development

 

 

227,702

 

 

 

73,020

 

 

 

1,484

 

 

(l)

 

 

302,206

 

Selling, general and administrative

 

 

115,450

 

 

 

40,813

 

 

 

8,363

 

 

(i)

 

 

164,626

 

Total cost and operating expenses

 

 

348,431

 

 

 

113,833

 

 

 

 

 

 

 

 

472,111

 

Loss from operations

 

 

(217,270

)

 

 

(73,336

)

 

 

 

 

 

 

 

(300,453

)

Non-operating income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain from sale of priority review voucher

 

 

108,000

 

 

 

 

 

 

 

 

 

 

 

108,000

 

Investment income, net

 

 

19,701

 

 

 

8,436

 

 

 

(5,940

)

 

(j)

 

 

22,197

 

Other income, net

 

 

1,217

 

 

 

 

 

 

 

 

 

 

 

1,217

 

Interest expense

 

 

 

 

 

(3,874

)

 

 

 

 

 

 

 

(3,874

)

Total non-operating income, net

 

 

128,918

 

 

 

4,562

 

 

 

 

 

 

 

 

127,540

 

Loss before income taxes

 

 

(88,352

)

 

 

(68,774

)

 

 

 

 

 

 

 

(172,913

)

Income tax expense

 

 

(7,144

)

 

 

(418

)

 

 

 

 

(k)

 

 

(7,562

)

Net loss

 

 

(95,496

)

 

 

(69,192

)

 

 

 

 

 

 

 

(180,475

)

Net loss per share - basic

 

$

(1.02

)

 

 

 

 

 

 

 

 

 

$

(1.94

)

Net loss per share - diluted

 

$

(1.02

)

 

 

 

 

 

 

 

 

 

$

(1.94

)

Weighted-average number of common shares used in net loss per share - basic

 

 

93,234,195

 

 

 

 

 

 

 

 

 

 

 

93,234,195

 

Weighted-average number of common shares used in net loss per share - diluted

 

 

93,234,195

 

 

 

 

 

 

 

 

 

 

 

93,234,195

 

 


NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

 

1. Description of the Transaction

 

On November 12, 2025, Day One and Mersana entered into an Agreement and Plan of Merger, or the Merger Agreement. Pursuant to the Merger Agreement, the Company commenced a tender offer to acquire all of the issued and outstanding shares of common stock of Mersana, or the Target Shares, for (i) $25.00 net per Target Share, payable in cash, without interest, plus (ii) one CVR per Target Share which represents the right to receive milestone payments of up to an aggregate of $30.25 per share in cash upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement.

 

On January 6, 2026, the transaction closed and the Company acquired all outstanding Target Shares at a price of $25.00 per share in cash, plus one non-tradable CVR per share to receive certain potential milestone payments of up to an aggregate of $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash.

 

2. Basis of Presentation

 

The unaudited pro forma condensed combined financial statements and related notes are prepared in accordance with Article 11 of Regulation S-X and present the historical financial information of Day One and Mersana, the pro forma effects of the Acquisition and certain acquisition accounting adjustments described herein.

 

The business combination of Mersana has been accounted for using the acquisition method of accounting as per the provisions of ASC 805, using the fair value concepts defined in ASC Topic 820 – Fair Value Measurement and based on the historical financial statements of Day One and the historical consolidated financial statements of Mersana. Under ASC 805, all assets acquired and liabilities assumed in a business combination are generally recognized and measured at their assumed acquisition date fair value, while transaction costs and restructuring costs associated with the business combination are expensed as incurred. The excess of preliminary purchase price over the fair value of assets acquired and liabilities assumed, has been recorded in goodwill. The pro forma adjustments represent management’s best estimates and are based upon information currently available and certain assumptions that the management of Day One believes are reasonable under the circumstances.

 

The unaudited pro forma financial statements are provided for illustrative purposes only and do not purport to represent what the actual consolidated results of the companies would have been had the Acquisition occurred on the dates indicated, nor are they necessarily indicative of future consolidated results of operations of the Company. The pro forma statements of operations neither reflect the costs of any integration activities, nor the synergies and benefits that may result from realization of any anticipated revenue growth or operational efficiencies expected to result from the Acquisition.

 

There were no material transactions between Day One and Mersana during the periods presented in the unaudited pro forma condensed combined financial statements.

 

3. Preliminary Purchase Price Accounting and Allocation

 

Preliminary purchase price

 

The preliminary purchase price consideration consists of the cash paid and the estimated fair value of the CVRs at the Closing Date as follows (in thousands):

 

Cash

 

$

125,027

 

Estimated fair value of contingent value rights

 

 

48,000

 

Total estimated fair value of consideration transferred

 

$

173,027

 

 

Preliminary purchase price allocation

 

Day One’s purchase price allocation for the Acquisition is preliminary and subject to revision as additional information regarding the fair value of the assets acquired and liabilities assumed becomes available. Due to the nature of the tangible assets acquired and liabilities assumed, Day One has determined that the carrying amounts of such assets and liabilities as of the Closing Date approximate their respective fair values. In accordance with ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, the Company has recognized deferred revenue as of the Closing Date, measured in accordance with ASC 606, Revenue from Contracts with Customers.

 


Day One has engaged a third-party valuation specialist to assist in the valuation of the identifiable intangible assets acquired and the consideration associated with the CVR. The preliminary valuation is based on the financial information available as of the Closing Date, consideration of comparable transactions, and currently available, but limited, forecasted financial information. The unaudited pro forma condensed combined financial statements may differ from the Company’s final purchase price accounting for a number of reasons, including the fact that the estimates of fair values of assets acquired and liabilities assumed as of the Closing Date are preliminary and therefore subject to change within the measurement period (no longer than one year from the Closing Date), at which time the valuation analysis and other analyses are finalized.
 

The following table sets forth a preliminary allocation of the estimated purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed as of September 30, 2025, with the excess recorded as goodwill (in thousands):

 

Cash and cash equivalents

 

$

56,391

 

Accounts receivable

 

 

168

 

Prepaid expenses and other current assets

 

 

2,140

 

Property and equipment

 

 

163

 

Deposits and other long-term assets

 

 

500

 

Intangible assets

 

 

196,850

 

Total assets acquired

 

$

256,212

 

Accounts payable

 

 

2,393

 

Accrued expenses and other current liabilities

 

 

14,813

 

Current and long-term portion of deferred revenue

 

 

102,724

 

Total liabilities assumed

 

$

119,930

 

Net assets acquired

 

$

136,282

 

Total estimated fair value of consideration transferred

 

 

173,027

 

Preliminary goodwill

 

$

36,745

 

 

4. Transaction Accounting Adjustments

 

The pro forma adjustments are based on our preliminary estimates and assumptions that are subject to change. The following are the pro forma adjustments included in the unaudited pro forma condensed combined balance sheet as of September 30, 2025 and give effect to the Acquisition as if it had occurred on that date:

 

(a) Represents the liquidation of $81.8 million of Day One’s short-term investments to fund the Acquisition, reflecting the amount of cash that would have been required to be transferred had the Acquisition closed on September 30, 2025. This cash conversion is reflected as a corresponding increase in cash and cash equivalents.

 

(b) Represents the total purchase consideration of $173.0 million, consisting of cash consideration of $125.0 million and a liability for the preliminary estimated fair value of contingent consideration of $48.0 million ($8.3 million recorded under Contingent consideration, current portion and $39.7 million recorded under Long-term portion of contingent consideration based on estimated timing of potential payments) as of the Closing Date. The potential payments are based on the achievement of (i) regulatory milestones, (ii) commercial milestones and (iii) specified net sales thresholds. The aggregate undiscounted maximum amount of contingent consideration that could become payable under the arrangement is approximately $156.0 million. The Company is not able to reasonably estimate the range of undiscounted outcomes at this time due to significant uncertainties regarding the probability and timing of achieving the specified milestones. These uncertainties include development risk, regulatory approval risk, and the variability of future commercial performance. The contingent consideration is classified as a liability in accordance with ASC 805 and will be remeasured at fair value at each reporting date and subsequent changes in the fair value post-Closing Date will be recognized in the combined statement of operations.

 

(c) Represents an adjustment of $1.3 million for the directors and officers tail insurance policy required per the terms of the Merger Agreement. The policy covers claims related to pre-Closing Date events and, in accordance with ASC 805, is reflected as a reduction of Mersana’s net assets as of the Closing Date, as it relates solely to pre-combination activities and does not represent a post-combination operating asset.

 

(d) Represents the elimination of the Mersana right-of-use asset and corresponding lease liability. As of the Closing Date, the remaining lease term was less than twelve months and did not include any purchase options. Accordingly, the Company applied the short-term lease recognition exemption and did not recognize a right-of-use asset or lease liability in accordance with ASC 805.

 


(e) Represents the identifiable intangible assets acquired by the Company at the preliminary estimated fair value as of the Closing Date. The identifiable intangible assets consist of a contract-based license asset with a preliminary estimated fair value of $22.4 million and an in-process research and development, or IPR&D, asset with a preliminary estimated fair value of $174.5 million. The contract-based license intangible asset has a preliminary estimated useful life of seventeen years. IPR&D assets are considered indefinite-lived until completion or abandonment of the associated research and development efforts and therefore are not amortized during that period.

 

(f) Represents the recognition of goodwill resulting from the Acquisition, calculated as the excess of the total consideration transferred over the preliminary estimated fair values of the identifiable tangible and intangible assets acquired and liabilities assumed of Mersana as of September 30, 2025.

 

(g) Represents direct and incremental expense related to the Acquisition incurred by Day One of $4.8 million for advisory and legal fees payable directly to third party vendors and $3.7 million of employee equity cash settlement obligations related to accelerated vesting of Mersana equity awards as per the Merger Agreement. The Company made these adjustments to accrued liabilities and accumulated deficit as these expenses were recognized subsequent to the Day One September 30, 2025 historical balance sheet presented.

 

(h) Represents the elimination of Mersana historical equity balances as of September 30, 2025.

 

The pro forma adjustments are based on our preliminary estimates and assumptions that are subject to change. The following are the pro forma adjustments included in the unaudited pro forma consolidated combined statement of operations for the nine months ended September 30, 2025 and year ended December 31, 2024 giving effect to the Acquisition as if it had occurred on January 1, 2024.

 

(i) Represents an increase in selling, general and administrative expenses of $1.0 million for the nine months ended September 30, 2025 and $8.4 million for the year ended December 31, 2024. The increase for the nine months ended September 30, 2025 consists of estimated amortization expense related to the finite-lived intangible asset, as described in Note 4(e), calculated on a straight-line basis over the asset’s estimated useful life. The increase for the year ended December 31, 2024 consists of (i) $7.1 million of direct and incremental expenses related to the Acquisition incurred by Day One of $4.8 million related to advisory and legal fees payable to third-party vendors and $2.3 million related to employee equity cash settlement obligations that are not reflected in Day One’s historical financial information, as described in Note 4(g) and (ii) $1.3 million of estimated amortization expense related to the finite-lived intangible asset, calculated on a straight-line basis over the asset’s estimated useful life. The estimated amortization expense is recorded within selling, general and administrative expenses because the contract-based license intangible asset does not require Day One to perform research and development activities and is not associated with an approved product. The advisory and legal fees and the equity cash settlement obligations are nonrecurring in nature and are not expected to have a continuing impact on the combined results.

 

(j) Represents interest income forgone of $2.9 million for the nine months ended September 30, 2025, and $5.9 million for the year ended December 31, 2024 as a result of the liquidation of $81.8 million of Day One’s short-term investments, as described in Note 4(a). The interest income forgone was calculated using the Company’s actual average rates of return realized on its investment portfolio during the respective periods presented.

 

(k) No income tax effect has been reflected for the pro forma transaction accounting adjustments. Mersana has significant net operating loss carryforwards and other deferred tax assets, which are fully offset by a full valuation allowance because future realization is not expected. Consequently, although taxable temporary differences give rise to deferred tax liabilities, no net deferred tax liability is recognized and no current tax benefit or expense was reflected in the periods presented. The accounting for opening balance sheet deferred income taxes is preliminary. The estimates may differ from amounts the Company will calculate after completing a detailed analysis, and the difference could have a material effect on the accompanying unaudited pro forma financial statements. The actual tax impact in periods subsequent to the Acquisition may differ due to changes in the valuation allowance assessment, jurisdictional earnings mix and other discrete items.

 

(l) Represents an increase in research and development expenses of $1.5 million for the year ended December 31, 2024 for employee equity cash settlement obligations that are not reflected in Day One’s historical financial information, as described in Note 4(g).